Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in the NAD
salvage pathway of mammalian cells and is overexpressed in numerous types of cancers …

Highlights•NAMPT is overexpressed in cancers, associating with a poor prognosis and
tumor progression.•Extensive efforts have been made to improve efficacy and safety of early …

Alterations in mTOR signalling molecules, including RICTOR amplification, have been
previously described in many cancers, particularly associated with poor prognosis. In this …

Approximately 70% of human breast cancers express estrogen receptor-α (ERα), providing
a potential target for endocrine therapy. However, 30% to 40% of patients with ER+ breast …

Nicotinamide phosphoribosyltransferase (NAMPT) is a key rate-limiting enzyme in the
nicotinamide adenine dinucleotide (NAD+) salvage pathway, primarily catalyzing the …

Cancer cells are highly dependent on Nicotinamide phosphoribosyltransferase (NAMPT)
activity for proliferation, therefore NAMPT represents an interesting target for the …

The p21-activated kinase 4 (PAK4) is a member of the PAKs family. It is overexpressed in
multiple tumor tissues. Pharmacological inhibition of PAK4 attenuates proliferation …

Over 95% of Pancreatic ductal adenocarcinomas (PDA) carry mutations in the oncogene
KRas which has been proven to be a difficult drug target. P21-activated kinase 4 (PAK4) …

Simple Summary The screening of experimental and repurposing drugs has enormous
potential for rapid clinical impact, particularly when new therapeutic strategies are sought …

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most difficult to treat
cancers. Gemcitabine is still the standard of care treatment for PDAC but with modest …